TABLE 4.
Preboost serum RSV-neutralizing titers in AGMs boosted with DS-Cav1/B3TMCT and peak mean titers of post-boosting replication and RSV-neutralizing antibodies in 2-month, 6-month, and 15-month study cohorts
| Study cohort | Pre-boosting serum RSV-neutralizing titer (log2 PRNT) (mean ± SEM)a | Peak titer in NP samples (TCID50/ml) (mean ± SEM)b | Peak titer in TL samples (TCID50/ml) (mean ± SEM)b | Post-boosting serum RSV-neutralizing titer with complement (log2 PRNT) (mean)c | Post-boosting serum RSV-neutralizing titer without complement (log2 PRNT) (mean)c |
|---|---|---|---|---|---|
| ∼2 mo | 8.1 ± 2.1 | 4.9 ± 1.0 | 3.4 ± 1.2 | 14.5 | 12.9 |
| ∼6 mo | 6.1 ± 1.7 | 5.4 ± 0.5 | 5.2 ± 0.9 | 15.6 | 11.8 |
| ∼15 mo | 4.7 ± 0.7 | 5.4 ± 2.3 | 4.8 ± 1.1 | 14.9 | 12.1 |
a
Sera were collected 2 weeks (∼2-month and ∼15-month studies) or 35 days (∼6-month study) before boosting and were analyzed by the RSV PRN assay with added complement.
b
NP and TL samples were collected daily and every second day, respectively, for 10 days post-boost and titrated by limiting dilution. Means were calculated for each day, and the peak mean titer SEM for each virus is shown.
c
Sera were collected 2 weeks following boosting and analyzed by the RSV PRN assay with or without complement, as indicated.